Applied DNA Sciences - APDN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.50
  • Forecasted Upside: 684.52%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.19
▼ -0.1259 (-39.70%)

This chart shows the closing price for APDN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Applied DNA Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APDN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APDN

Analyst Price Target is $1.50
▲ +684.52% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Applied DNA Sciences in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 684.52% upside from the last price of $0.19.

This chart shows the closing price for APDN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Applied DNA Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/10/2024HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $1.50
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$1.50 ➝ $7.00
2/9/2024HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $30.00
12/8/2023HC WainwrightLower TargetBuy ➝ Buy$80.00 ➝ $40.00
8/24/2023HC WainwrightReiterated RatingBuy ➝ Buy$80.00
8/14/2023HC WainwrightLower TargetBuy ➝ Buy$100.00 ➝ $80.00
7/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00
3/30/2023HC WainwrightReiterated RatingBuy$100.00
3/23/2023HC WainwrightReiterated RatingBuy$100.00
2/10/2023HC WainwrightReiterated RatingBuy$100.00
1/6/2023HC WainwrightReiterated RatingBuy$100.00
12/16/2022Maxim GroupLower Target$120.00 ➝ $60.00
12/15/2022HC WainwrightLower TargetBuy$160.00 ➝ $100.00
8/15/2022HC WainwrightBoost Target$160.00
5/16/2022HC WainwrightLower TargetNA$120.00 ➝ $80.00
2/14/2022Maxim GroupLower Target$360.00 ➝ $120.00
2/11/2022HC WainwrightLower TargetBuy$160.00 ➝ $120.00
12/10/2021HC WainwrightLower TargetBuy$220.00 ➝ $160.00
11/30/2021HC WainwrightUpgradeBuy$220.00
10/13/2021HC WainwrightReiterated RatingBuy$220.00
8/13/2021HC WainwrightLower TargetBuy$260.00 ➝ $220.00
5/14/2021Maxim GroupReiterated RatingBuy$360.00
4/22/2021HC WainwrightLower TargetBuy$280.00 ➝ $260.00
2/12/2021Roth CapitalInitiated CoverageBuy$480.00
1/11/2021HC WainwrightReiterated RatingReduce ➝ Buy$360.00 ➝ $280.00
12/18/2020HC WainwrightLower TargetBuy$400.00 ➝ $240.00
11/30/2020HC WainwrightLower TargetBuy$440.00 ➝ $400.00
8/18/2020HC WainwrightReiterated RatingBuy$440.00
8/11/2020Maxim GroupReiterated RatingBuy
7/31/2020Maxim GroupReiterated RatingBuy$420.00
7/20/2020HC WainwrightReiterated RatingBuy$360.00 ➝ $440.00
7/17/2020Maxim GroupReiterated RatingBuy$420.00
7/2/2020HC WainwrightInitiated CoverageBuy$360.00
5/15/2020Maxim GroupReiterated RatingBuy$420.00
5/5/2020Maxim GroupBoost TargetBuy$160.00 ➝ $360.00
4/17/2020Maxim GroupReiterated RatingBuy$160.00
3/20/2020Maxim GroupReiterated RatingBuy$160.00
12/13/2019Maxim GroupReiterated RatingBuy$160.00
12/4/2019Maxim GroupReiterated RatingBuy$160.00
11/22/2019Maxim GroupUpgradeHold ➝ Buy$160.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/3/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/3/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
6/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/2/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/1/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/31/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/30/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Applied DNA Sciences logo
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Read More

Today's Range

Now: $0.19
Low: $0.18
High: $0.21

50 Day Range

MA: $1.02
Low: $0.29
High: $2.54

52 Week Range

Now: $0.19
Low: $0.18
High: $22.80

Volume

20,672,754 shs

Average Volume

3,772,740 shs

Market Capitalization

$188.33 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Applied DNA Sciences?

The following sell-side analysts have issued reports on Applied DNA Sciences in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for APDN.

What is the current price target for Applied DNA Sciences?

1 Wall Street analysts have set twelve-month price targets for Applied DNA Sciences in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 373.0%. HC Wainwright has the highest price target set, predicting APDN will reach $1.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.50 for Applied DNA Sciences in the next year.
View the latest price targets for APDN.

What is the current consensus analyst rating for Applied DNA Sciences?

Applied DNA Sciences currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APDN will outperform the market and that investors should add to their positions of Applied DNA Sciences.
View the latest ratings for APDN.

What other companies compete with Applied DNA Sciences?

How do I contact Applied DNA Sciences' investor relations team?

Applied DNA Sciences' physical mailing address is 50 HEALTH SCIENCES DRIVE, STONY BROOK NY, 11790. The technology company's listed phone number is (631) 240-8800 and its investor relations email address is [email protected]. The official website for Applied DNA Sciences is www.adnas.com. Learn More about contacing Applied DNA Sciences investor relations.